Chronic GVHD Risk Factors and Prevention

Video

Panelists consider key risk factors for chronic GVHD, including the degree of donor transplant matching, patient age, intensity of conditioning, use of ablative doses of total-body radiation, and presence of acute GVHD.

Transcript:

John F. DiPersio, MD, PhD: What do you consider risk factors for chronic GVHD [graft-vs-host disease]?

Pashna N. Munshi, MD: If they’ve had acute GVHD or repeated flares, they’re certainly at a much higher a risk of chronic GVHD. Mismatched transplants would be another reason to have chronic GVHD.

Hannah Choe, MD: Older age.

Pashna N. Munshi, MD: And older age. Yes.

Yi-Bin Chen, MD: The intensity of conditioning and the use of ablative doses of total-body radiation are well-described risk factors. As Pashna mentioned, the degree of matching is the leading 1. As you move into match donors, you have others that haven’t been identified in large studies. It’s fascinating that the presence of acute graft-vs-host disease, as the patient journey continues, has long been the leading risk factor for development of chronic. With the latest innovations in GVHD prevention, that might be changing. It will be an interesting to see if we’re able to separate acute alloreactivity from chronic. If you look at the randomized bone marrow vs PBSC [peripheral blood stem cell] in the CTN 0201 trial, the risk of acute wasn’t all that different, but chronic was significantly lower with bone marrow. The recent approval of abatacept, for unrelated donor transplant prophylaxis, came on heels of decreasing acute significantly but did not seem to have a great signal in the reduction of chronic graft-vs-host disease. With newer methods of prophylaxis, we may start to see a separation.

Pashna N. Munshi, MD: What are your thoughts on that regarding post-transplant [PT] cyclophosphamide, which is used as GVHD prophylaxis…and nonhaploidentical settings?

John F. DiPersio, MD, PhD: It’s hard to put all these studies together, but there are 3 things that seem to have impacted the rate of chronic GVHD in the setting of transplantation. The use of bone marrow vs peripheral blood. Obviously, there’s less chronic GVHD. That’s 1 thing. The second thing is that post-transplant cyclophosphamide has primarily altered the rates of chronic GVHD. It’s still unclear because I always think of acute GVHD as the precipitating event for the development of chronic GVHD, the biology. It reminds me that I don’t know as much as I think I know about this. The third is ATGAM. Lots of crazy studies have been done with ATGAM around the world, but 1 thing that seems to come from all these studies is that there seems to be a lower rate of chronic GVHD primarily. Other than those things, there hasn’t been anything. The abatacept study doesn’t suggest and didn’t really demonstrate a big difference in chronic GVHD.

I don’t know what you all think about that, but those are the only studies that have shown me that there’s a difference in outcome for chronic GVHD, G-CSF [granulocyte colony-stimulating factor], ATGAM, and PT cyclophosphamide. As we look at other agents in the future, that will be the case as well. JAK inhibitors haven’t been studied as well in the chronic GVHD setting, but they may also impact chronic GVHD. Yi-Bin?

Yi-Bin Chen, MD: It will be interesting to see where we move. If we’re still going to view this GVHD prevention as 1 package or if we’re going to separate them, giving certain things to prevent acute. Then after transplant, depending how the patient is doing, we can make interventions to prophylax or prevent chronic graft-vs-host disease. Hopefully we’ll become a bit more elegant in how we do this going forward, instead of giving 1 package and saying it will hopefully work to prevent both.

Transcript edited for clarity.

Recent Videos
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content
Improving Disease Modification and Immune Responses in Myelofibrosis With Pelabresib

Improving Disease Modification and Immune Responses in Myelofibrosis With Pelabresib

ONCOLOGY Staff
November 16th 2024
Article

David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202

Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202

American Society for Transplantation and Cellular Therapy
October 30th 2024
Article

Posttransplant cyclophosphamide leads to unique changes in vascular biomarkers, revealing a distinct toxicity profile compared to other GVHD prophylaxis regimens.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Lower-Risk MDS Population Has Enduring RBC-TI Following Imetelstat Therapy

Ashling Wahner
September 8th 2024
Article

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Data from the PERSEUS trial support the benefit of D-VRd and DR maintenance as a standard of care in transplant-eligible newly diagnosed multiple myeloma.

Subcutaneous Daratumumab Combo Improves MRD-Negative Status in NDMM

Chris Ryan
September 7th 2024
Article

Data from the PERSEUS trial support the benefit of D-VRd and DR maintenance as a standard of care in transplant-eligible newly diagnosed multiple myeloma.